Menopause after breast cancer
This is not medical advice — it is general information based on what you searched for that may help.
General information based on published sources and the symptoms you searched for. This isn't medical or legal advice, a diagnosis or a treatment plan. Please consult a doctor about your own symptoms. If your symptoms are severe or sudden, seek urgent care.
Evidence:Strong evidence
This page may not apply to you if:
- Every treatment decision after breast cancer must be coordinated with your oncology team, including checking CYP2D6 drug interactions if you take tamoxifen
Chemotherapy, ovarian suppression, and endocrine therapies (such as tamoxifen or aromatase inhibitors) frequently trigger sudden, severe hot flashes, night sweats, and vaginal dryness. Because systemic hormone therapy is generally contraindicated after breast cancer, management focuses on proven non-hormonal options coordinated with your oncology team.
1. Evidence-backed non-hormonal options for hot flashes
In its 2023 Nonhormone Therapy Position Statement, The Menopause Society identified several Level I–II non-hormonal treatments that reduce vasomotor symptom frequency or distress in randomized trials:
- Cognitive behavioral therapy (CBT) and clinical hypnosis (Level I): Reduce how much hot flashes and night sweats interfere with daily life and sleep, with zero drug interactions.
- Selected SSRIs/SNRIs, gabapentin, and oxybutynin (Levels I–II): Prescription medications shown to reduce hot flashes. Crucial medication interaction check: If you take tamoxifen, certain SSRIs (such as paroxetine and fluoxetine) inhibit the CYP2D6 enzyme that activates tamoxifen, so your oncologist and prescriber must choose an option that does not interfere with your endocrine therapy.
- Neurokinin 3 (NK3) antagonists (Level I): Non-hormonal options such as fezolinetant (Veozah); discuss safety and required liver blood monitoring with your oncologist.
By contrast, over-the-counter herbal remedies and menopause supplements are not recommended by The Menopause Society for hot flashes (Levels I–II) and can interact with cancer treatments.
2. Managing vaginal dryness and painful sex
Both The Menopause Society (2020) and ACOG (2021) recommend regular non-hormonal vaginal moisturisers (used several times per week for continuous tissue hydration) alongside personal lubricants during sexual activity as first-line care. If severe symptoms persist despite consistent non-hormonal care, any discussion of low-dose local vaginal therapy must take place directly with your oncologist.
Questions to take to your oncology and menopause team
Build a printable question sheet in our treatment conversation builder and log your symptoms in the private symptom tracker:
- Which Level I non-hormonal prescription options for hot flashes are safe alongside my specific cancer history and current endocrine therapy (such as tamoxifen or an aromatase inhibitor)?
- Can you refer me to a CBT programme for menopausal hot flashes and insomnia?
- Which non-hormonal vaginal moisturiser schedule do you recommend for daily comfort?
Where are you right now?
Still tracking
Not sure if your symptoms fit? Start tracking your daily patterns.
Log and spot your patterns with the symptom checklist →Ready to talk to a doctor
Have an upcoming appointment? Bring structured questions and your history.
Prepare your 10-minute doctor appointment questions →Already on treatment
Evaluating your response or wondering what to adjust next?
Explore evidence-graded treatment and lifestyle options →Questions people ask
Are "natural phytoestrogen" supplements safe to take for hot flashes after breast cancer?
Do not start over-the-counter herbal or phytoestrogen supplements without oncology approval. The Menopause Society (2023) does not recommend herbal supplements or soy extracts for hot flashes because trial evidence does not show consistent benefit, and concentrated extracts may have uncertain effects or drug interactions.
What can help vaginal dryness on tamoxifen or an aromatase inhibitor?
Regular non-hormonal vaginal moisturisers (applied several times a week) and personal lubricants during sex are recommended as first-line care. Any consideration of low-dose local vaginal therapy requires joint review with your oncologist.
Related pages
References
- Shufelt CL, Brown V, Carpenter JS et al.. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause (The North American Menopause Society, now The Menopause Society), 2023.
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause: The Journal of The Menopause Society, 2020.
- Treatment of Symptoms of the Genitourinary Syndrome of Menopause: Clinical Consensus No. 2. American College of Obstetricians and Gynecologists, 2021.
Change log
- : Published clinical guide on managing menopause symptoms after breast cancer